Terms ending in 2036
Every in-force patent on Ambrx, Inc.'s record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,550,190 | Phosphate Based Linkers for Intracellular Delivery of Drug Conjugates In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,773,150 | Antibody Peptide Conjugates That Have Agonist Activity at Both the Glucagon and Glucagon-Like Peptide 1 Receptors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 10,800,826 | Antibody Peptide Conjugates That Have Agonist Activity at Both the Glucagon and Glucagon-Like Peptide 1 Receptors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 11,851,488 | ANTI-CD3-FOLATE Conjugates and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Ambrx, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.